Cover Image
Market Research Report

Autosomal Dominant Polycystic Kidney DiseasePipeline Insight, 2019

Published by DelveInsight Business Research LLP Product code 910654
Published Content info 60 Pages
Delivery time: 1-2 business days
Price
Back to Top
Autosomal Dominant Polycystic Kidney DiseasePipeline Insight, 2019
Published: September 1, 2019 Content info: 60 Pages
Description

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Overview:

" Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autosomal Dominant Polycystic Kidney Disease pipeline landscape is provided which includes the disease overview and Autosomal Dominant Polycystic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Autosomal Dominant Polycystic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autosomal Dominant Polycystic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Understanding

"Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. It is the most common inherited disorder of the kidneys. Symptoms usually develop between the ages of 30 and 40, but they can begin earlier, even in childhood. The most common symptoms are pain in the back and the sides and headaches. Other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, brain aneurysms, and diverticulosis. According to National Institute of Diabetes and Digestive and Kidney Diseases, Autosomal dominant means the patient can get the PKD gene mutation, or defect, from only one parent. Researchers have found two different gene mutations that cause ADPKD. Most people with ADPKD have defects in the PKD1 gene, and 1 out of 6 or 1 out of 7 people with ADPKD have a defective PKD2 gene.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Autosomal Dominant Polycystic Kidney Disease (ADPKD) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Autosomal Dominant Polycystic Kidney Disease (ADPKD) pipeline report covers 7+ companies. Some of the key players include Palladio Biosciences (Lixivaptan), Kadmon Corporation (Tesevatinib) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Analytical Perspective by DelveInsight

  • In-depth Autosomal Dominant Polycystic Kidney Disease (ADPKD) Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Autosomal Dominant Polycystic Kidney Disease report provides an overview of therapeutic pipeline activity for Autosomal Dominant Polycystic Kidney Disease across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Autosomal Dominant Polycystic Kidney Disease therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Autosomal Dominant Polycystic Kidney Disease Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Autosomal Dominant Polycystic Kidney Disease

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across Autosomal Dominant Polycystic Kidney Disease to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Autosomal Dominant Polycystic Kidney Disease R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Autosomal Dominant Polycystic Kidney Disease in licensing and out licensing strategies by identifying prospective partners with progressing projects for Autosomal Dominant Polycystic Kidney Disease to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Table of Contents
Product Code: DIPI0368

Table of Contents

1. Report Introduction

2. Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  • 2.1. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Disease Overview
  • 2.2. Autosomal Dominant Polycystic Kidney Disease (ADPKD) History
  • 2.3. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Symptoms
  • 2.4. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Causes
  • 2.5. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pathophysiology
  • 2.6. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Diagnosis
    • 2.6.1. Diagnostic Guidelines

3. Autosomal Dominant Polycystic Kidney Disease (ADPKD) Current Treatment Patterns

  • 3.1. Treatment Guidelines

4. Autosomal Dominant Polycystic Kidney Disease (ADPKD)- DelveInsight's Analytical Perspective

  • 4.1. In-depth Commercial Assessment
    • 4.1.1. Autosomal Dominant Polycystic Kidney Disease companies collaborations, Licensing, Acquisition -Deal Value Trends
      • 4.1.1.1. Assessment Summary
    • 4.1.2. Autosomal Dominant Polycystic Kidney Disease Collaboration Deals
      • 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
      • 4.1.2.2. Autosomal Dominant Polycystic Kidney Disease Acquisition Analysis
  • 4.2. Clinical Assessment of Pipeline Drugs
    • 4.2.1. Assessment by Phase of Development
    • 4.2.2. Assessment by Product Type (Mono / Combination)
      • 4.2.2.1. Assessment by Stage and Product Type
    • 4.2.3. Assessment by Route of Administration
      • 4.2.3.1. Assessment by Stage and Route of Administration
    • 4.2.4. Assessment by Molecule Type
      • 4.2.4.1. Assessment by Stage and Molecule Type
    • 4.2.5. Assessment by MOA
      • 4.2.5.1. Assessment by Stage and MOA

5. Autosomal Dominant Polycystic Kidney Disease Pipeline Therapeutics

  • 5.1. Late Stage Products (Phase-III)
    • 5.1.1. Comparative Analysis
  • 5.2. Mid Stage Products (Phase-II)
    • 5.2.1. Comparative Analysis
  • 5.3. Early Stage Products (Phase-I)
    • 5.3.1. Comparative Analysis
  • 5.4. Pre-clinical and Discovery Stage Products
    • 5.4.1. Comparative Analysis
  • 5.5. Inactive Products

6. Autosomal Dominant Polycystic Kidney Disease -Products Analysis

  • 6.1. Product Profiles
    • 6.1.1. Lixivaptan : Palladio Biosciences
      • 6.1.1.1. Product Description
      • 6.1.1.1.1. Product Overview
      • 6.1.1.1.2. Mechanism of Action
      • 6.1.1.2. Research and Development
      • 6.1.1.2.1. Clinical Studies
      • 6.1.1.2.1.1. Detailed Study Description
      • 6.1.1.2.1.2. Study Results
      • 6.1.1.2.1.3. Clinical Trials: Tabular View
      • 6.1.1.3. Product Development Activities
      • 6.1.1.3.1. Tabulated Product Summary
      • 6.1.1.3.1.1. General Description Table
    • 6.1.2. Tesevatinib : Kadmon Corporation
      • 6.1.2.1. Product Description
      • 6.1.2.1.1. Product Overview
      • 6.1.2.1.2. Mechanism of Action
      • 6.1.2.2. Research and Development
      • 6.1.2.2.1. Clinical Studies
      • 6.1.2.2.1.1. Detailed Study Description
      • 6.1.2.2.1.2. Study Results
      • 6.1.2.2.1.3. Clinical Trials: Tabular View
      • 6.1.2.3. Product Development Activities
      • 6.1.2.3.1. Tabulated Product Summary
      • 6.1.2.3.1.1. General Description Table

To be continued in the report…………………………

7. Recent Technologies

8. Autosomal Dominant Polycystic Kidney Disease Key Companies

  • 8.1. Regulus Therapeutics
  • 8.2. Endocyte
  • 8.3. GLG Pharma
  • 8.4. Palladio Biosciences
  • 8.5. DiscoveryBioMed
  • 8.6. Sanofi Genzyme
  • 8.7. Exelixis

9. Autosomal Dominant Polycystic Kidney Disease Key Products

  • 9.1. RGLS 4326
  • 9.2. Research programme: autosomal dominant polycystic kidney disease therapeutics
  • 9.3. GLG 801
  • 9.4. Lixivaptan
  • 9.5. Research programme: anti-proliferative therapeutics
  • 9.6. Venglustat
  • 9.7. Tesevatinib

10. Dormant and Discontinued Products

  • 10.1. Dormant Products
    • 10.1.1. Reasons for being dormant
  • 10.2. Discontinued Products
    • 10.2.1. Reasons for the discontinuation

11. Autosomal Dominant Polycystic Kidney Disease - Unmet Needs

12. Autosomal Dominant Polycystic Kidney Disease - Future Perspectives

13. Appendix

14. Report Methodology

  • 14.1. Secondary Research
  • 14.2. Expert Panel Validation

List of Tables

  • TABLE 1 Diagnostic Guidelines
  • TABLE 2 Treatment Guidelines
  • TABLE 3 Assessment Summary
  • TABLE 4 Company-Company Collaborations (Licensing / Partnering) Analysis
  • TABLE 5 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Acquisition Analysis
  • TABLE 6 Assessment by Phase of Development
  • TABLE 7 Assessment by Product Type (Mono / Combination)
  • TABLE 8 Assessment by Stage and Product Type
  • TABLE 9 Assessment by Route of Administration
  • TABLE 10 Assessment by Stage and Route of Administration
  • TABLE 11 Assessment by Molecule Type
  • TABLE 12 Assessment by Stage and Molecule Type
  • TABLE 13 Assessment by MOA
  • TABLE 14 Assessment by Stage and MOA
  • TABLE 15 Late Stage Products (Phase-III)
  • TABLE 16 Mid Stage Products (Phase-II)
  • TABLE 17 Early Stage Products (Phase-I)
  • TABLE 18 Pre-clinical and Discovery Stage Products
  • TABLE 19 Inactive Products
  • TABLE 20 Dormant Products
  • TABLE 21 Discontinued Products

List of Figures

  • Figure 1 Disease Overview
  • Figure 2 History
  • Figure 3 Symptoms
  • Figure 4 Causes
  • Figure 5 Pathophysiology
  • Figure 6 Diagnostic Guidelines
  • Figure 7 Treatment Guidelines
  • Figure 8 Autosomal Dominant Polycystic Kidney Disease (ADPKD) companies collaborations, Licensing, Acquisition -Deal Value Trends
  • Figure 9 Company-Company Collaborations (Licensing / Partnering) Analysis
  • Figure 10 Autosomal Dominant Polycystic Kidney Disease (ADPKD) Acquisition Analysis
  • Figure 11 Assessment by Phase of Development
  • Figure 12 Assessment by Product Type (Mono / Combination)
  • Figure 13 Assessment by Stage and Product Type
  • Figure 14 Assessment by Route of Administration
  • Figure 15 Assessment by Stage and Route of Administration
  • Figure 16 Assessment by Molecule Type
  • Figure 17 Assessment by Stage and Molecule Type
  • Figure 18 Assessment by MOA
  • Figure 19 Assessment by Stage and MOA
  • Figure 20 Late Stage Products (Phase-III)
  • Figure 21 Mid Stage Products (Phase-II)
  • Figure 22 Early Stage Products (Phase-I)
  • Figure 23 Pre-clinical and Discovery Stage Products
  • Figure 24 Inactive Products
  • Figure 25 Dormant Products
  • Figure 26 Discontinued Products
  • Figure 27 Unmet Needs
Back to Top